INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dynavax Technologies Corporation and Encourages Investors with Losses to Contact the Firm

Accesswire 13-Jan-2017 8:27 PM

IRVINE, CA / ACCESSWIRE / January 13, 2017 / Khang & Khang LLP (the "Firm") announces a class action lawsuit against Dynavax Technologies Corporation ("Dynavax" or the "Company") (NASDAQ: DVAX). Investors who purchased or otherwise acquired shares between March 10, 2014 and November 11, 2016 inclusive (the "Class Period"), are encouraged to contact the Firm by the January 17, 2017 lead plaintiff motion deadline.

If you purchased shares of Dynavax during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that Dynavax made false and/or misleading statements and/or failed to disclose: that the phase 3 HBV-23 trial for the Company's lead vaccine product, HEPLISAV-B, was not designed in accordance with the U.S. Food and Drug Administration's concerns and issues; that the Company failed to provide sufficient information to the FDA in its Revised Biologics License Application for the drug; that Dynavax's resources will not be sufficient for the Company to advance the HEPLISAV-B program on its own; and that, as a result of the above, the Company's financial statements and statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis. On November 14, 2016, Dynavax announced that it received a Complete Response Letter from the U.S. Food and Drug Administration requesting additional information on the Company's HEPLISAV-B product in connection with its Biologics License Application. When this information was disclosed, shares of Dynavax declined in value, causing investors serious harm.

If you wish to learn more about this lawsuit at no charge to you, or if you have any questions regarding this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at

This press release may constitute Attorney Advertising in some jurisdictions.


Khang & Khang LLP Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474

SOURCE: Khang & Khang LLP

Image for Press Release 373332

Wait, Before You Leave...

Receive Anticipated Price Moves into Earnings

Enter your email address below to receive FREE daily information about expected earnings moves and upcoming earnings.
Market Chameleon